Brief: Glenmark Pharma's Swiss Unit Enters Licensing Deal With Lotus International

Lotus Pharmaceutical

20/01/2022 03:17

Jan 20 (Reuters) - Glenmark Pharmaceuticals Ltd  GLEN.NS :
    * GLENMARK SPECIALTY S.A. AND LOTUS INTERNATIONAL PTE. LTD.
ENTER
INTO EXCLUSIVE LICENSING AGREEMENT
    * DEAL TO COMMERCIALIZE RYALTRIS NASAL SPRAY IN SINGAPORE,
HONG
KONG AND VIETNAM
    * UNDER DEAL CO WILL BE RESPONSIBLE FOR MANUFACTURE AND
SUPPLY OF
RYALTRIS
    * LOTUS INTERNATIONAL TO BE RESPONSIBLE FOR
COMMERCIALIZATION OF
RYALTRIS
    * CO TO GET UPFRONT PAYMENT, REGULATORY AND SALES BASED
MILESTONE
PAYMENTS FROM LOTUS
    * RYALTRIS INDICATED FOR TREATMENT OF SYMPTOMS ASSOCIATED
WITH
ALLERGIC RHINITIS

Source text for Eikon:  ID:nBSET2Qq7 
Further company coverage:  GLEN.NS 

 ((Reuters.Briefs@thomsonreuters.com;))